Interplay between hepatitis B virus and the type I interferon system and new therapeutic strategies

Jie Liang Chen, Jian Hua Li, Xiao Nan Zhang, Min Wu, Bi Sheng Shi, Zhong Fang, Zheng Hong Yuan

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Hepatitis B virus (HBV) infection has been one of the most important public health problems, however, no complete cure is currently available. Although interferon (IFN)-α has been clinically used as a drug for chronic hepatitis B therapy because of its advantages including a higher rate of HBsAg/HBeAg seroconversion and a lower rate of recurrence after cessation of treatment, only 20%-40% of patients respond well to IFN therapy, thus hampering its clinical application. In recent years, based on the in vitro HBV replication and infection cell models, animal models and patient cohort with hepatitis B and by using a variety of methods, studies have been made. On the one hand, to identify new mechanisms underlying the IFN-and IFN-induced genes-mediated anti-HBV activities and signaling transduction, on the other hand, to reveal the effect and mechanisms of HBV replication and viral proteins in regulating the innate immune signaling pathways and IFN induction and antiviral action, based on which new strategies and approaches for optimization of IFN-based therapy and for a HBV cure have been further explored. This review mainly introduces the research findings of author's group and the future development is prospected.

Original languageChinese (Simplified)
Pages (from-to)793-798
Number of pages6
JournalFudan University Journal of Medical Sciences
Issue number6
Publication statusPublished - 25 Nov 2017
Externally publishedYes

Cite this